Last edition
News about Global Pharma
Vanda Pharmaceuticals Receives Orphan Drug Designation Granted for VGT-1849A
VGT-1849A is a novel ASO treatment candidate for PV and other JAK2-driven hematologic malignancies.
Global Pharma | 21/12/2024 | By Aishwarya | 1014
LSPedia to Expand Globally with New Office Launch in India in January 2025
The Hyderabad office will play a key role in LSPedia's global growth strategy, delivering exceptional service to customers in Bahrain, Bangladesh, Singapore, Switzerland, UK, and the balance of the EU.
Global Pharma | 21/12/2024 | By Aishwarya | 513
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Depakote Sprinkle Capsules, 125 mg, of AbbVie Inc.
Global Pharma | 20/12/2024 | By Manvi | 265
Novo Holdings Completes Acquisition of Catalent
With the completion of the transaction, holders of Catalent common stock are entitled to receive USD 63.50 per share in cash, representing a premium of approximately 47.5 percent to the 60-day volume-weighted average price as of February 2, 2024.
Global Pharma | 20/12/2024 | By Aishwarya | 433
Merck Signs Exclusive Global License Deal with Hansoh Pharma for Oral GLP-1 Receptor Agonist
Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535.
Global Pharma | 19/12/2024 | By Aishwarya | 591
MTPA Signs Deal with Dewpoint to Advance Small Molecule Condensate Modulator
The collaboration focuses on developing a novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), furthering MTPC's commitment to advancing innovation in ALS and central nervous system (CNS) diseases.
Global Pharma | 19/12/2024 | By Aishwarya | 407
Noema Pharma Closes its Series B Financing Round with USD 147 Million Capital Funding
The new financing will support Noema Pharma’s four active Phase 2 trials, with key data readouts anticipated in 2025.
Global Pharma | 18/12/2024 | By Aishwarya | 799
Lilly and EVA Pharma Secure Approval to Distribute Locally Manufactured Insulin in Egypt
Under this agreement, Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges.
Global Pharma | 18/12/2024 | By Aishwarya | 995
AbbVie to Acquire Nimble Therapeutics to Expand its Immunology Pipeline
AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to help drive rapid discovery and optimization of peptide candidates for a range of targets.
Global Pharma | 18/12/2024 | By Aishwarya | 881
ENEA-Tech Invests EUR 6 Million in BetaGlue Therapeutics
This EUR 6 million investment from ENEA-Tech follows the EUR 8 million equity financing round and the EUR 10 million EIC Accelerator Award announced in June of this year.
Global Pharma | 17/12/2024 | By Aishwarya | 381
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy